Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Feb;82(4):833–837. doi: 10.1054/bjoc.1999.1008

Expression of telomerase-associated protein 1 and telomerase reverse transcriptase in hepatocellular carcinoma

N Toshikuni 1, K Nouso 1, T Higashi 1, H Nakatsukasa 1, T Onishi 1, T Kaneyoshi 1, Y Kobayashi 1, K Kariyama 1, K Yamamoto 1, T Tsuji 1
PMCID: PMC2374388  PMID: 10732755

Abstract

To know whether two protein components of human telomerase (human telomerase-associated protein 1 (hTEP1) and human telomerase reverse transcriptase (hTERT) are useful markers for telomerase activation in human liver diseases, we examined mRNA levels of these and telomerase activity in human liver samples. Twenty-three human hepatocellular carcinomas (HCCs) and corresponding adjacent livers were analysed for hTEP1 and hTERT expression by semiquantitative reverse transcription-polymerase chain reaction, and for telomerase activity by a telomeric repeat amplification protocol assay. Thirteen liver samples (ten HCCs and three dysplastic nodules) that were biopsied with 21-gauge needles were analysed for hTERT expression. hTEP1 was expressed in all samples examined. No correlation between hTEP1 expression and telomerase activity was observed. hTERT expression significantly correlated with telomerase activity (P< 0.001). The positivity of hTERT for HCC and corresponding non-cancerous liver was 100% and 30.4% respectively (P< 0.001). Seventy-four per cent (17/23) of HCCs showed strong hTERT expression, but none of the non-cancerous liver tissues did. hTERT expression of the 21-gauge needle biopsied specimens showed no significant difference from that of the surgical samples. The present study revealed that hTERT is strongly expressed in most HCCs, and that hTERT but not hTEP1 is a key component regulating telomerase activity in human liver. © 2000 Cancer Research Campaign

Keywords: hepatocellular carcinoma, telomerase, hTERT, hTEP1

Full Text

The Full Text of this article is available as a PDF (97.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allsopp R. C., Vaziri H., Patterson C., Goldstein S., Younglai E. V., Futcher A. B., Greider C. W., Harley C. B. Telomere length predicts replicative capacity of human fibroblasts. Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10114–10118. doi: 10.1073/pnas.89.21.10114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Avilion A. A., Piatyszek M. A., Gupta J., Shay J. W., Bacchetti S., Greider C. W. Human telomerase RNA and telomerase activity in immortal cell lines and tumor tissues. Cancer Res. 1996 Feb 1;56(3):645–650. [PubMed] [Google Scholar]
  3. Bodnar A. G., Ouellette M., Frolkis M., Holt S. E., Chiu C. P., Morin G. B., Harley C. B., Shay J. W., Lichtsteiner S., Wright W. E. Extension of life-span by introduction of telomerase into normal human cells. Science. 1998 Jan 16;279(5349):349–352. doi: 10.1126/science.279.5349.349. [DOI] [PubMed] [Google Scholar]
  4. Counter C. M., Avilion A. A., LeFeuvre C. E., Stewart N. G., Greider C. W., Harley C. B., Bacchetti S. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J. 1992 May;11(5):1921–1929. doi: 10.1002/j.1460-2075.1992.tb05245.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Feng J., Funk W. D., Wang S. S., Weinrich S. L., Avilion A. A., Chiu C. P., Adams R. R., Chang E., Allsopp R. C., Yu J. The RNA component of human telomerase. Science. 1995 Sep 1;269(5228):1236–1241. doi: 10.1126/science.7544491. [DOI] [PubMed] [Google Scholar]
  6. Harrington L., McPhail T., Mar V., Zhou W., Oulton R., Bass M. B., Arruda I., Robinson M. O. A mammalian telomerase-associated protein. Science. 1997 Feb 14;275(5302):973–977. doi: 10.1126/science.275.5302.973. [DOI] [PubMed] [Google Scholar]
  7. Hisatomi H., Nagao K., Kanamaru T., Endo H., Tomimatsu M., Hikiji K. Levels of telomerase catalytic subunit mRNA as a predictor of potential malignancy. Int J Oncol. 1999 Apr;14(4):727–732. doi: 10.3892/ijo.14.4.727. [DOI] [PubMed] [Google Scholar]
  8. Hytiroglou P., Kotoula V., Thung S. N., Tsokos M., Fiel M. I., Papadimitriou C. S. Telomerase activity in precancerous hepatic nodules. Cancer. 1998 May 15;82(10):1831–1838. [PubMed] [Google Scholar]
  9. Kim N. W., Piatyszek M. A., Prowse K. R., Harley C. B., West M. D., Ho P. L., Coviello G. M., Wright W. E., Weinrich S. L., Shay J. W. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994 Dec 23;266(5193):2011–2015. doi: 10.1126/science.7605428. [DOI] [PubMed] [Google Scholar]
  10. Kolquist K. A., Ellisen L. W., Counter C. M., Meyerson M., Tan L. K., Weinberg R. A., Haber D. A., Gerald W. L. Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. Nat Genet. 1998 Jun;19(2):182–186. doi: 10.1038/554. [DOI] [PubMed] [Google Scholar]
  11. Morin G. B. The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell. 1989 Nov 3;59(3):521–529. doi: 10.1016/0092-8674(89)90035-4. [DOI] [PubMed] [Google Scholar]
  12. Nakagawa T., Seki T., Shiro T., Wakabayashi M., Imamura M., Itoh T., Tamai T., Nishimura A., Yamashiki N., Matsuzaki K. Clinicopathologic significance of protein induced vitamin K absence or antagonist II and alpha-fetoprotein in hepatocellular carcinoma. Int J Oncol. 1999 Feb;14(2):281–286. doi: 10.3892/ijo.14.2.281. [DOI] [PubMed] [Google Scholar]
  13. Nakamura T. M., Morin G. B., Chapman K. B., Weinrich S. L., Andrews W. H., Lingner J., Harley C. B., Cech T. R. Telomerase catalytic subunit homologs from fission yeast and human. Science. 1997 Aug 15;277(5328):955–959. doi: 10.1126/science.277.5328.955. [DOI] [PubMed] [Google Scholar]
  14. Nakayama J., Saito M., Nakamura H., Matsuura A., Ishikawa F. TLP1: a gene encoding a protein component of mammalian telomerase is a novel member of WD repeats family. Cell. 1997 Mar 21;88(6):875–884. doi: 10.1016/s0092-8674(00)81933-9. [DOI] [PubMed] [Google Scholar]
  15. Nakayama J., Tahara H., Tahara E., Saito M., Ito K., Nakamura H., Nakanishi T., Tahara E., Ide T., Ishikawa F. Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nat Genet. 1998 Jan;18(1):65–68. doi: 10.1038/ng0198-65. [DOI] [PubMed] [Google Scholar]
  16. Nouso K., Urabe Y., Higashi T., Nakatsukasa H., Hino N., Ashida K., Kinugasa N., Yoshida K., Uematsu S., Tsuji T. Telomerase as a tool for the differential diagnosis of human hepatocellular carcinoma. Cancer. 1996 Jul 15;78(2):232–236. doi: 10.1002/(SICI)1097-0142(19960715)78:2<232::AID-CNCR7>3.0.CO;2-N. [DOI] [PubMed] [Google Scholar]
  17. Raeymaekers L. A commentary on the practical applications of competitive PCR. Genome Res. 1995 Aug;5(1):91–94. doi: 10.1101/gr.5.1.91. [DOI] [PubMed] [Google Scholar]
  18. Reichman T. W., Albanell J., Wang X., Moore M. A., Studzinski G. P. Downregulation of telomerase activity in HL60 cells by differentiating agents is accompanied by increased expression of telomerase-associated protein. J Cell Biochem. 1997 Oct 1;67(1):13–23. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES